SPDR S&P Biotech ETF (XBI)
NYSEArca - NYSEArca Real Time Price. Currency in USD
It wasn’t so long ago that investors could count on health-care stocks not only to outperform the market, but to lead it. For much of the past five years, the sector was one of the best-performing in the Standard & Poor’s 500 index, thanks in no small part to the eye-popping returns generated by drug makers, especially biotechnology companies. Adding to the frenzy, big drug makers were paying hefty premiums to acquire small rivals with innovative pipelines.
- Benzinga•6 days ago
Drug pricing has been one of the hot topics of the year. As Citron Research's controversial executive editor Andrew Left said last month, “Regulating the price of pharmaceuticals and eliminating price ...